Definitive Contract 75A50122C00066

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded Esperovax Inc. a $484,643 firm fixed price definitive contract to develop host-directed therapeutic candidates for mitigating long-term effects of respiratory distress. The contract was awarded under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought proposals for candidates aiding long-term outcomes from lung injury through Area of...

This definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Orasure Technologies Inc. is valued at $710,310 to support the development of a rapid antigen test for COVID-19. The contract was awarded under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002 and will deliver research and development efforts towards a host-directed therapeutic to aid long-term outcomes from lung...

This is a $207,236 firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Biolink Life Sciences, Inc., a woman-owned small business. The contract is part of the Biolink program, which is a randomized, double-blinded, placebo-controlled, parallel-design, multi-center, adaptive study to investigate whether treatment with ramatroban for 28 days reduces the risk of subsequent development of post-acute sequelae of SARS-CoV-2 (PASC) in...

This federal contract award, valued at $749,549.00, was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Immunexpress Inc., a for-profit foreign-owned company. The contract is for the "ASSESSMENT & TRIAGE OF PATIENTS WITH ESCALATING SIGNS OF COVID-19 DISEASE USING A HOST RESPONSE TEST FOR SEPSIS" and is a definitive, firm-fixed-price contract with a period of performance ending on June 10, 2023. The contract award originated from a Broad...

The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Regeneron Pharmaceuticals Inc. under Other Transaction Authority for the development of novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens. The contract, awarded on September 21, 2017, with an ultimate completion date of September 24, 2027, operates under cost-sharing pricing and does not utilize a set-aside...

The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $749,000 firm fixed-price contract to Gen1E Lifesciences Inc. on September 22, 2023, for support in advancing patient stratification and endotyping approaches related to GEN-1124, a novel therapeutic candidate for acute respiratory distress syndrome (ARDS). The contract, which carries no set-aside designation, is structured as a definitive contract with a completion...

This federal contract award, W911QY2190008, was issued by the Joint PEO Chemical and Biological Defense, a subcomponent of the U.S. Department of the Army, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $62,096,250.00 Other Transaction Agreement is for the development of a "COVID-19" Monoclonal Antibody (MAB) Sponsorship Prototype. Resilience Government Services, a technology-focused biomanufacturing company, has previously received federal...

This is a prime contract award to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services. The $14,898,362.53 cost-plus-fixed-fee contract is for biomedical research and development. It has a period of performance through December 31, 2011 and does not have a set-aside designation. Resilience Government Services is a technology-focused...

This contract was awarded by the National Center for Advancing Translational Sciences (NCATS), which is a civilian agency under the National Institutes of Health (NIH), to Lifeline Cell Technology, LLC, a subsidiary of International Stem Cell Corporation, to purchase human small airway epithelial primary cells. The cells are being acquired to develop a 3D vascularized lung model to mimic SARS-CoV-2 viral infection, in support of COVID-19 research. The contract has a firm fixed price of...

This federal contract award is for $142,563.00 to Biosurfaces Inc., a for-profit vendor that provides medical and laboratory supplies, equipment, and services to the Department of Health and Human Services (HHS), primarily the National Institutes of Health (NIH). The award is for the provision of expandable lung alveolar epithelial cells in support of coronavirus (COVID-19) research conducted by the NIH's National Center for Advancing Translational Sciences. This non-competitive acquisition...